Jack Roth MD

Cardiovascular Surgery

Professor of Thoracic Surgery, University Tex Houston

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Thoracic Surgery - Independent, 1977 - 1980
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Surgery, 1975 - 1977
Johns Hopkins University School of MedicineInternship, Transitional Year, 1971 - 1972
Johns Hopkins University School of MedicineClass of 1971

PubMed

Mutation of SMARCA4 Induces Cancer Cell-Intrinsic Defects in the Enhancer Landscape and Resistance to Immunotherapy.
Yawen Wang, Ismail M Meraz, Md Qudratullah, Sasikumar Kotagiri, Yanyan Han
Cancer Research. 2025-03-13
Machine Learning Prediction of Financial Toxicity in Patients with Resected Lung Cancer.
Nathaniel Deboever, Qasem Al-Tashi, Michael Eisenberg, Maliazurina B Saad, Mara B Antonoff
Journal of the American College of Surgeons. 2025-03-03
1 citations
Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.
Ferdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, Yu Qian, Xin Sun
Nature. 2025-03-01

Journal Articles

Inhibition of thioredoxin/thioredoxin Reductase Induces Synthetic Lethality in Lung Cancers with Compromised Glutathione Homeostasis
John V Heymach, Stephen G Swisher, Jack A Roth, John D Minna, Clinical Cancer Research
Landscape of EGFR -Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Post-Progression in EGFR-Mutant NSCLC
Stephen G Swisher, Vassiliki A Papadimitrakopoulou, John V Heymach, Jack A Roth, Jianjun Zhang, William N William, Bonnie S Glisson, Clinical Cancer Research
Validation of the 12-Gene Predictive Signature for Adjuvant Chemotherapy Response in Lung Cancer
Cesar Moran, Jack A Roth, Yang Xie, John D Minna, Vassiliki A Papadimitrakopoulou, John V Heymach, Stephen G Swisher, Clinical Cancer Research

Long-Term Benefit of SABR for Operable Early-Stage NSCLC Shown in New StudySeptember 13th, 2021
How Genprex Took an Abandoned Pipeline Drug and Turned It into Oncoprex, an Innovative Treatment for Non-Small Cell Lung CancerOctober 17th, 2018
Genprex Reports New Pre-Clinical Data Showing Strong Anti-Tumor Effect of TUSC2 in Combination with PD-1 Checkpoint Blockade in Lung CancerApril 2nd, 2017
Join now to see all

BAY AREA & ANDERSON TEAM AGAINST ACQUIRED RESISTANCE - U54 PROGRAM (BAATAAR-UP)UNIVERSITY OF CALIFORNIA, SAN FRANCISCO2017–2027
P-5: Translation Of The 3p21.3 Gene FUS1 Into Pathway-Targeted Molecular TherapyNational Cancer Institute2008–2011
Developmental Research ProgramNational Cancer Institute2008–2011
Career Development ProgramNational Cancer Institute2008–2011
Restoration Of Apoptosis In CancerNational Cancer Institute1999–2003
Radiation Sensitivity/Apoptosis Induction In Cancer Cells--P53 RestorationNational Cancer Institute1999–2002
Modification Of Oncogene ExpressionNational Cancer Institute1992–1994
Training Of Academic Thoracic Surgical OncologistsNational Cancer Institute1988–1992
Tumor Antigens Expressed By Oncogene-Transformed CellsNational Cancer Institute1987–1991